Clinical trial Recruiting at 1 site Interventional Ages 18 to 75

Left vs right subthalamic nucleus deep brain stimulation: how it changes thinking and mood in Parkinson’s

Official title: Impact of Subthalamic Nucleus Deep Brain Stimulation on COGnitive and PSYchiatric Symptoms in Parkinson's Disease

Run by Insel Gruppe AG, University Hospital Bern · NCT07777419 · Data updated 2026-11-12

This study tests whether turning DBS on the left or the right side of the brain changes cognition and mood in people with Parkinson’s disease.

Quick facts

Study typeInterventional
Ages18 Years to 75 Years
SexAll
Enrollment20 (estimated)
SponsorInsel Gruppe AG, University Hospital Bern
Academic / other
Locations1 site (Bern)
StatusRecruiting
StartedAugust 1, 2026
Main results expectedJuly 31, 2028
Study endsDecember 31, 2028
Registry record updatedSeptember 4, 2026
Trial IDNCT07777419 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults with Parkinson’s disease already treated with STN-DBS, fluent in German or French, and with Montreal Cognitive Assessment score of at least 20.

Probably not a fit

Patients without meaningful cognitive or mood symptoms or with contraindicating conditions may not experience benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Researchers will compare how turning DBS off in the left hemisphere versus the right hemisphere affects cognitive and psychiatric symptoms in people with Parkinson’s disease who already have STN-DBS. The trial uses a crossover-like design where participants are assessed in DBS-off states for each hemisphere to see if laterality influences outcomes. The study builds on prior findings that DBS improves motor symptoms and may impact non-motor symptoms, but exact effects by stimulation side are not yet clear. Enrollment requires language fluency in German or French, and sufficient cognitive function, with clear safety exclusions for other brain conditions or severe psychiatric issues. Results could clarify whether left- or right-sided STN stimulation offers different benefits for cognition and mood.

Why it matters

Potential benefit: If successful, the findings could guide personalized DBS programming to optimize cognitive and psychiatric outcomes in PD.

How similar studies have gone: Previous DBS work shows motor benefits and possible non-motor effects, but direct side-specific cognitive/psychiatric outcomes are not yet clearly demonstrated.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Diagnosed with Parkinson's disease
* Treated with subthalamic nucleus deep brain stimulation (STN-DBS)
* For part I: General research consent for the analysis of routine clinical data
* For part II of the study: ability to provide informed consent
* native German or French speaker
* Montreal Cognitive Assessment with score ≥ 20

Exclusion Criteria:

* Atypical Parkinsonism
* Other disease affecting the brain (e.g. Alzheimer's disease, vascular dementia, multiple sclerosis, stroke, traumatic brain injury, non-provoked epilepsy, brain tumour, etc.)
* Haemorrhage during implantation of STN-DBS, which resulted in permanent cognitive or physical impairment
* Schizophrenia, ongoing substance abuse, bipolar disorder or autism
* For part II: Severe depressive disorder and/or suicidality
* Insufficient quality or lack of brain imaging data pre and/or post STN-DBS

Where it's running

  • University Hospital Inselspital, Berne
    Bern, Switzerland
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.